薛侃, 陕飞, 季加孚. 养正消积胶囊应用于恶性肿瘤及癌前病变治疗中安全性的Meta分析[J]. 中国肿瘤临床, 2013, 40(21): 1318-1323. DOI: 10.3969/j.issn.1000-8179.20131476
引用本文: 薛侃, 陕飞, 季加孚. 养正消积胶囊应用于恶性肿瘤及癌前病变治疗中安全性的Meta分析[J]. 中国肿瘤临床, 2013, 40(21): 1318-1323. DOI: 10.3969/j.issn.1000-8179.20131476
shu
Kan XUE, Fei SHAN, Jiafu JI. Meta-analysis of the safety of Yangzhengxiaoji capsule for the treatment of cancer and precancerosis[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 40(21): 1318-1323. DOI: 10.3969/j.issn.1000-8179.20131476
Citation: Kan XUE, Fei SHAN, Jiafu JI. Meta-analysis of the safety of Yangzhengxiaoji capsule for the treatment of cancer and precancerosis[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 40(21): 1318-1323. DOI: 10.3969/j.issn.1000-8179.20131476
shu

养正消积胶囊应用于恶性肿瘤及癌前病变治疗中安全性的Meta分析

Meta-analysis of the safety of Yangzhengxiaoji capsule for the treatment of cancer and precancerosis

    摘要
  • 摘要:
      目的  评价养正消积胶囊治疗恶性肿瘤及癌前病变的安全性。
      方法  通过计算机检索中英文数据库，包括CNKI（中国期刊全文专题数据库）、万方电子期刊、维普全文电子期刊（中国科技期刊数据库），以及PubMed、Science Direct Online、MEDLINE@EBSCO，纳入养正消积胶囊治疗恶性肿瘤及癌前病变的临床试验研究。利用Cochrane图书馆手册5.0推荐方法对纳入研究进行质量评价、数据提取，最后采用Revman 5.0软件进行Meta分析。
      结果  本研究共纳入文献19篇，采用养正消积胶囊治疗患者总计2 125例，Meta分析结果显示，养正消积胶囊辅助化/放疗组的骨髓抑制、白细胞下降、血小板下降、消化道反应、恶心/呕吐、肝脏毒性不良反应发生率显著低于单纯化/放疗组（P < 0.05），肾脏毒性、心脏毒性以及神经毒性发生率不高于单纯化疗组（P>0.05）。
      结论  养正消积胶囊在治疗恶性肿瘤及癌前病变的应用中具有良好的安全性。

     

    Abstract:
      Objective  To evaluate the safety of Yangzhengxiaoji capsules for the treatment of cancer and precancerosis.
      Methods  Clinical trials and studies were collected by searching Chinese and English databases, including CNKI, WANFANG database, VIP information database, Pubmed, ScinenceDirect Online, and MEDLINE@EBSCO. The clinical data of Yangzhengxiaoji capsule for the treatment of cancer and pre-cancerosis were included. The quality of the included studies was then evaluated. Related data were extracted with reference to Cochrane Handbook 5.0. Afterward, meta-analysis was conducted using Revman 5.0 software.
      Results  A total of 19 studies focusing on 2 125 patients receiving Yangzhengxiaoji capsules were included and investigated in this meta-analysis. Results showed that the adverse reaction rates of myelosuppression, WBC and platelet decrease, gastrointestinal reaction, nausea/vomiting, and hepatotoxicity were significantly lower in the trial groups with Yangzhengxiaoji capsule-assisted chemotherapy/radiotherapy than in the control groups with chemotherapy/ radiotherapy only (P < 0.05). The adverse reaction rates of nephrotoxicity, cardiotoxicity, and neurotoxicity were not statistically different between the trial groups and the control groups (P>0.05).
      Conclusion  Yangzhengxiaoji capsule could be safely administered to treat cancer and precancerosis.

     

    • HTML全文
    • 参考文献(22)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回